The efficiency and safety of rapid acting insulin, glulisine, in the diabetic patients treated with intensive insulin therapy

Trial Profile

The efficiency and safety of rapid acting insulin, glulisine, in the diabetic patients treated with intensive insulin therapy

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Sep 2013

At a glance

  • Drugs Insulin glulisine (Primary)
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms BANDRA
  • Most Recent Events

    • 30 Aug 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top